Mendelian Susceptibility to Mycobacterial Disease (MSMD)
A rare genetic disorder of the interferon-gamma immune pathway that leaves affected individuals selectively vulnerable to severe or disseminated infection with weakly virulent mycobacteria, including BCG vaccine strains.
- Interferon-Gamma Pathway Disorder
- Specialist Immunology Review
- Targeted Antimycobacterial Therapy
- Typical Onset
- Infancy to Adulthood
- Inheritance Pattern
- AR / AD / X-linked
- Key Genes
- IFNGR1, IFNGR2, IL12B, STAT1
- Key Pathway
- IL-12/IFN-gamma Axis
Condition Overview
Mendelian Susceptibility to Mycobacterial Disease (MSMD) is a rare group of inherited disorders that impair the interleukin-12 / interferon-gamma signaling pathway, which is essential for controlling intracellular pathogens such as mycobacteria.
Unlike broader combined immunodeficiencies, individuals with MSMD often have largely normal immune function against most everyday pathogens, but are selectively susceptible to severe, recurrent, or disseminated infection with weakly virulent mycobacteria, including BCG vaccine strains and environmental nontuberculous mycobacteria, as well as occasionally Salmonella or other intracellular organisms.
Because the clinical picture can otherwise look like an isolated, unusual infection rather than a classic immunodeficiency, MSMD is frequently underdiagnosed. Recognizing the pattern, especially disseminated BCG disease after vaccination, is key to timely genetic evaluation and targeted management.
Types and Subtypes
MSMD is genetically heterogeneous, with more than a dozen genes implicated. The subtypes below reflect some of the more frequently identified molecular causes.
Symptoms and Signs
The hallmark of MSMD is infection with organisms that are usually harmless in people with intact IL-12/IFN-gamma signaling.
Causes and Risk Factors
MSMD results from inherited defects disrupting the interleukin-12/interferon-gamma circuit that activates macrophages to kill intracellular mycobacteria.
Diagnosis and Investigations
Diagnosis requires identifying the causative pathogen alongside functional and genetic evidence of an IL-12/IFN-gamma pathway defect.
Disease Severity and Risk Stratification
MSMD does not use a tumor-style staging system; severity is generally categorized by extent of infection and underlying genetic defect.
Standard Treatment Options
Treatment combines targeted antimycobacterial therapy with strategies to support the underlying immune pathway defect.
Advanced & Emerging Therapies
For severe or refractory cases, advanced cellular and immune-targeted approaches are being explored alongside conventional antimycobacterial therapy.
Cellular Therapy
Allogeneic Hematopoietic Stem Cell Transplantation
Considered in select patients with severe, recurrent disease related to complete pathway gene defects.
Immunotherapy
Recombinant Interferon-Gamma
Used adjunctively in certain partial receptor defects to enhance macrophage activation.
Precision Medicine
Genotype-Guided Treatment Selection
Treatment approach is increasingly tailored to the specific gene and variant identified, since response to interferon-gamma therapy differs by subtype.
Biomarkers & Precision Medicine
Functional and genetic markers guide diagnosis and help individualize treatment by genetic subtype.
When a Second Opinion May Be Important
Because MSMD spans many genetic subtypes with different treatment implications, specialist input can refine both diagnosis and management.
Clinical Trials & Research
Prognosis & Outcome Factors
Prognosis in MSMD varies widely by genetic subtype, ranging from a relatively mild course with a single treatable infection episode to recurrent, severe, or disseminated disease.
Supportive Care and Living with MSMD
Supportive care focuses on infection prevention, treatment adherence, and family education about the unique infection risk profile.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients and families with MSMD obtain specialist immunology and infectious disease report review, coordinate second opinions on antimycobacterial and adjunctive therapy, and connect with hospitals experienced in managing rare primary immunodeficiencies.
Get a free case reviewFrequently Asked Questions
MSMD is a group of rare inherited disorders that impair the interleukin-12/interferon-gamma pathway, leaving affected individuals selectively vulnerable to infection with weakly virulent mycobacteria.
MSMD is caused by mutations in genes such as IFNGR1, IFNGR2, IL12B, IL12RB1, STAT1, or NEMO that disrupt the IL-12/interferon-gamma signaling axis.
BCG is a weakly virulent mycobacterium; in genetically susceptible infants it can trigger disseminated infection, often providing the first clinical clue to the diagnosis.
Diagnosis combines identification of the causative mycobacterial organism with functional immune testing and genetic confirmation of a pathway gene defect.
Yes. Combination antimycobacterial therapy, sometimes alongside recombinant interferon-gamma, manages most cases; stem cell transplant is considered for the most severe genetic subtypes.
Most patients have largely normal responses to common pathogens, but some subtypes also carry increased risk for Salmonella or other intracellular infections.
Inheritance varies by gene and can be autosomal recessive, autosomal dominant, or X-linked, which affects recurrence risk within families.
Yes, milder genetic subtypes can present later in life, sometimes after exposure to environmental nontuberculous mycobacteria.
No, transplant is generally reserved for patients with complete pathway gene defects and severe, recurrent, or refractory disease.
Yes. CancerFax can help coordinate review of your immunology and genetic reports, facilitate second opinions on treatment strategy, and connect you with specialist hospitals experienced in rare primary immunodeficiencies, including cross-border coordination where needed.
Exploring Care Options for Mendelian Susceptibility to Mycobacterial Disease?
Send your medical reports for specialist review and connect with centers experienced in primary immunodeficiency and inherited metabolic-inflammatory disease management.